View in EDS HTML Full Text PDF Full Text

Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials.

Saved in:
Bibliographic Details
Title: Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials.
Authors: Giovannoni G; Queen Mary University of London, London, UK., Kappos L; Research Center for Clinical Neuroimmunology and Neuroscience and MS Center, University Hospital Basel and University of Basel, Basel, Switzerland., de Seze J; University Hospital of Strasbourg, Strasbourg, France., Hauser SL; University of California, San Francisco, CA, USA., Overell J; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Koendgen H; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Manfrini M; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Wang Q; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Wolinsky JS; McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA.
Source: European journal of neurology [Eur J Neurol] 2022 Apr; Vol. 29 (4), pp. 1238-1242. Date of Electronic Publication: 2021 May 05.
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Wiley Country of Publication: England NLM ID: 9506311 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-1331 (Electronic) Linking ISSN: 13515101 NLM ISO Abbreviation: Eur J Neurol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 33724637
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Giovannoni+G%22">Giovannoni G</searchLink>; Queen Mary University of London, London, UK.<br /><searchLink fieldCode="AU" term="%22Kappos+L%22">Kappos L</searchLink>; Research Center for Clinical Neuroimmunology and Neuroscience and MS Center, University Hospital Basel and University of Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22de+Seze+J%22">de Seze J</searchLink>; University Hospital of Strasbourg, Strasbourg, France.<br /><searchLink fieldCode="AU" term="%22Hauser+SL%22">Hauser SL</searchLink>; University of California, San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Overell+J%22">Overell J</searchLink>; F. Hoffmann-La Roche Ltd, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Koendgen+H%22">Koendgen H</searchLink>; F. Hoffmann-La Roche Ltd, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Manfrini+M%22">Manfrini M</searchLink>; F. Hoffmann-La Roche Ltd, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Wang+Q%22">Wang Q</searchLink>; F. Hoffmann-La Roche Ltd, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Wolinsky+JS%22">Wolinsky JS</searchLink>; McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229506311%22">European journal of neurology</searchLink> [Eur J Neurol] 2022 Apr; Vol. 29 (4), pp. 1238-1242. <i>Date of Electronic Publication: </i>2021 May 05.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley%22">Wiley </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9506311 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1468-1331 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2213515101%22">13515101 </searchLink><i>NLM ISO Abbreviation: </i>Eur J Neurol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=33724637
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/ene.14823
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1238
    Titles:
      – TitleFull: Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Giovannoni G
      – PersonEntity:
          Name:
            NameFull: Kappos L
      – PersonEntity:
          Name:
            NameFull: de Seze J
      – PersonEntity:
          Name:
            NameFull: Hauser SL
      – PersonEntity:
          Name:
            NameFull: Overell J
      – PersonEntity:
          Name:
            NameFull: Koendgen H
      – PersonEntity:
          Name:
            NameFull: Manfrini M
      – PersonEntity:
          Name:
            NameFull: Wang Q
      – PersonEntity:
          Name:
            NameFull: Wolinsky JS
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 04
              Text: 2022 Apr
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1468-1331
          Numbering:
            – Type: volume
              Value: 29
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: European journal of neurology
              Type: main
ResultId 1